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BACKGROUND
Factor Xa inhibitors – antithrombin III  
inhibitor anticoagulants indicated for venous 
thrombosis and pulmonary embolism – are 
widely prescribed, and adverse hematologic 
effects have been described in this setting. 
However, there are no current reports of 
intentional fondaparinux poisoning by self-injection.
METHODS
A novel case of a patient suffering from fondaparinux overdose 
by self-injection with serum concentration is reported. A 
49-year-old woman with a history of stiff person syndrome, 
recurrent pulmonary embolism, and depression prescribed 
fondaparinux presented to the ED after intentionally injecting 
herself with 13 syringes of her fondaparinux. She reported 
injecting them subcutaneously in her abdomen over the course 
of several minutes about 18 hours before coming to the ED. 
Each syringe contained 7.5 mg fondaparinux (total 97.5 mg). 
Her vital signs and laboratory testing were unremarkable 
(including routine toxicologic, renal, and coagulation studies).
RESULTS
The patient was admitted given no current recommendations 
regarding this poisoning and the potential for depot effect of 
large amounts of fondaparinux which could be absorbed. A 
serum anti-Xa fondaparinux concentration the day after 
admission measured >4.0 mg/L (therapeutic 0.50 mg/L). 
Physical exam showed multiple abdominal injection sites 
without excessive bleeding. She demonstrated no signs of 
bleeding in the hospital and was discharged to an inpatient 
psychiatric unit without sequelae on hospital day three.
DISCUSSION
There are currently no reported cases of intentional 
fondaparinux poisoning, and this patient had an uneventful 
course. Pharmacokinetics of the drug indicate rapid absorption 
after subcutaneous injection with peak concentrations within 
two hours. It is not metabolized and undergoes renal elimination 
unchanged. Large doses may have a depot effect with 
unknown toxicokinetics and potential for delayed complications.
CONCLUSION
Given the absence of consensus recommendations at this 
point, the authors recommend prolonged observation with 
intentional poisoning given the difficulty of hematologic 
monitoring, especially in those patients with abnormal renal 
function or evidence of bleeding. 
